financetom
Business
financetom
/
Business
/
GRAPHIC-SpaceX by the numbers: Six charts mapping businesses driving its IPO ambitions
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
GRAPHIC-SpaceX by the numbers: Six charts mapping businesses driving its IPO ambitions
Jun 11, 2026 3:38 AM

By Anhata Rooprai and Jaspreet Singh

June 11 (Reuters) - SpaceX's market debut on Friday is

expected to be the largest-ever IPO, capping the meteoric rise

of a company that has reshaped the space business with reusable

rockets and internet beamed from orbit and which now targets

space-based AI.

Aiming for a $1.75 trillion valuation that would instantly

rank it among the world's most valuable companies, SpaceX

is pitching itself as humanity's ticket to Mars.

Its financials, though, show a company whose aggressive

spending on computing power for AI and developing a new rocket

has overwhelmed the profits from its Starlink satellite internet

service.

Here are six charts that illustrate its business:

AI LOSSES OUTWEIGH BOOST FROM STARLINK

Last year, SpaceX's sales rose 33% to $18.67 billion, with

Starlink accounting for about 60% of the total thanks to its

about 10.3 million users across 9,600 satellites.

But merging with the money-losing xAI pushed the company to

a net loss of $4.94 billion last year, from a profit of $791

million in 2024, when the explosive growth of Starlink and its

reusable rocket launch business powered earnings.

SPACEX'S LAUNCH CADENCE SETS IT APART FROM RIVALS

SpaceX has gone from a single launch in 2006 to more than

two every week, far outpacing rivals and making it the go-to

launch partner for NASA and the Pentagon.

Its reusable Falcon 9 has powered that surge, while the

larger, still-in-development Starship is intended to carry crew

and cargo on an unprecedented scale.

Falcon Heavy essentially combines three Falcon 9 boosters to

form one of the world's most powerful rockets. It is capable of

lifting 64 metric tons to low-Earth orbit and currently launches

heavy military satellites and interplanetary probes.

XAI TRAILS AI RIVALS ANTHROPIC, OPENAI

SpaceX's biggest addressable market, it says, is AI. In

February, SpaceX acquired xAI and united two key parts of Musk's

business empire. But by many measures, xAI is behind rivals

Anthropic and OpenAI.

A recent report from finance startup Ramp showed that more

than 30% of its business customers were paying for Anthropic's

and OpenAI's AI services in April, with the Claude Code creator

overtaking OpenAI for the first time, while xAI's adoption

remained around 5%.

The data - based on Ramp's analysis of spending by about

50,000 customers - only captures a small slice of spending by

big enterprises on AI, an area where Anthropic is believed to be

the market leader.

SPACEX IS RAISING FUNDS AT A PRICEY MULTIPLE

Investors in the SpaceX IPO are being asked to pay a premium

that dwarfs the multiples at which some of the most valuable

tech companies trade. At $135 per share, SpaceX would trade at a

trailing price-to-sales multiple of roughly 94 - above companies

such as Nvidia ( NVDA ), Amazon ( AMZN ) and Meta and

closer to pure-play space peers such as Planet Labs and

Rocket Lab ( RKLB ), which trade at 50.4 and 115.4,

respectively, despite being younger companies.

Since SpaceX generated a loss last year, it cannot be

compared on a price-to-earnings ratio.

STARSHIP WILL LIFT SPACEX'S LAUNCH CAPACITY

The case for that premium rests partly on Starship, which is

designed to be reusable and carry over 100 metric tons to

low-Earth orbit, more than any other rocket flying today. This

would be crucial not just to SpaceX's launch business but also

to its ambitions to put AI data centers in orbit.

Current SpaceX rockets, Falcon 9 and Falcon Heavy, can carry

about 22.8 metric tons and 63.8 metric tons to low-Earth orbit,

respectively.

The Starship's test flight in May marked a major milestone ahead

of the IPO, successfully deploying mock satellites and

completing a controlled Indian Ocean splashdown despite minor

engine issues.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Bausch Health Notes Xifaxan 550 mg Selected For Medicare 2nd Round Negotiations
Bausch Health Notes Xifaxan 550 mg Selected For Medicare 2nd Round Negotiations
Jan 17, 2025
10:27 AM EST, 01/17/2025 (MT Newswires) -- Bausch Health Companies ( BHC ) , down near 1% at last look, on Friday said the Centers for Medicare and Medicaid Services (CMS) has selected Xifaxan (rifaximin) 550 mg tablets for the second round of negotiation as part of the Inflation Reduction Act. We look forward to engaging in open and transparent...
Goldman Sachs Raises CEO David Solomon's Compensation to $39 Million in 2024
Goldman Sachs Raises CEO David Solomon's Compensation to $39 Million in 2024
Jan 17, 2025
10:23 AM EST, 01/17/2025 (MT Newswires) -- Goldman Sachs Group ( GS ) said in a regulatory filing Friday its board has approved to increase Chief Executive David Solomon's total annual compensation to $39 million in 2024 from $31 million in 2023. Solomon and Chief Operating Officer John Waldron were also given restricted stock units valued at $80 million each...
US Treasury Dept issues sanctions related to Salt Typhoon hack
US Treasury Dept issues sanctions related to Salt Typhoon hack
Jan 17, 2025
WASHINGTON (Reuters) - The U.S. Treasury department on Friday issued cyber-related sanctions related to the Salt Typhoon hack on Singaporean Yin Kechen and cybersecurity company Sichuan Juxinhe Network Technology Co., according to a statement. ...
Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise
Zai Lab's Schizophrenia Drug Application Accepted by Chinese Regulator; Shares Rise
Jan 17, 2025
10:20 AM EST, 01/17/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said Friday that its new drug application for KarXT to treat adult patients with schizophrenia was accepted by China's National Medical Products Administration. The application is backed by results from a phase 1 China pharmacokinetics study, the phase 3 China study and data from global Emergent clinical programs,...
Copyright 2023-2026 - www.financetom.com All Rights Reserved